Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Amortization of Deferred Charges (2016 - 2017)

Historic Amortization of Deferred Charges for BioCorRx (BICX) over the last 3 years, with Q1 2017 value amounting to $9.4 million.

  • BioCorRx's Amortization of Deferred Charges rose 4300488.91% to $9.4 million in Q1 2017 from the same period last year, while for Dec 2017 it was $9.4 million, marking a year-over-year increase of 1390132.19%. This contributed to the annual value of $9.4 million for FY2017, which is 1390132.19% up from last year.
  • Per BioCorRx's latest filing, its Amortization of Deferred Charges stood at $9.4 million for Q1 2017, which was up 4300488.91% from $45152.0 recorded in Q4 2016.
  • BioCorRx's Amortization of Deferred Charges' 5-year high stood at $9.4 million during Q1 2017, with a 5-year trough of $14966.0 in Q2 2015.
  • In the last 3 years, BioCorRx's Amortization of Deferred Charges had a median value of $45152.0 in 2016 and averaged $1.4 million.
  • As far as peak fluctuations go, BioCorRx's Amortization of Deferred Charges tumbled by 6955.74% in 2016, and later soared by 4300488.91% in 2017.
  • BioCorRx's Amortization of Deferred Charges (Quarter) stood at $35488.0 in 2015, then grew by 27.23% to $45152.0 in 2016, then surged by 20637.16% to $9.4 million in 2017.
  • Its Amortization of Deferred Charges was $9.4 million in Q1 2017, compared to $45152.0 in Q4 2016 and $21722.0 in Q1 2016.